NRC Health Net Income (Loss) Available to Common Stockholders, Basic
NRC Health (NRC) reported Net Income (Loss) Available to Common Stockholders, Basic of -$3.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-04
- NRC Health net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$3.30M.
- NRC Health net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $3.09M, a 46.62% decline year-over-year.
- NRC Health net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $1.68M, a 74.36% decline year-over-year.
- NRC Health net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $3.99M, a 29.78% decline year-over-year.
- NRC Health net income (loss) available to common stockholders, basic for fiscal 2025 was $11.29M, a 54.43% decline from fiscal 2024.
- NRC Health net income (loss) available to common stockholders, basic for fiscal 2024 was $24.78M, a 19.97% decline from fiscal 2023.
- NRC Health net income (loss) available to common stockholders, basic for fiscal 2023 was $30.96M, a 2.58% decline from fiscal 2022.
- NRC Health net income (loss) available to common stockholders, basic for fiscal 2022 was $31.78M, a 15.12% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.30M 10-Q · filed 2026-08-04 | -$214.00K 10-Q · filed 2026-08-04 | $1.47M derived: sum of 3 quarters · filed 2026-08-04 | $5.46M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.09M 10-Q · filed 2026-05-06 | $4.77M derived: sum of 2 quarters · filed 2026-05-06 | $8.77M derived: sum of 3 quarters · filed 2026-05-06 | $8.57M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.68M derived: sum of 2 quarters · filed 2026-03-05 | $5.49M derived: sum of 3 quarters · filed 2026-08-04 | $11.29M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.99M 10-Q · filed 2025-11-07 | $3.80M derived: sum of 2 quarters · filed 2026-08-04 | $9.61M 10-Q · filed 2025-11-07 | $16.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$190.00K 10-Q · filed 2026-08-04 | $5.59M 10-Q · filed 2026-08-04 | $12.16M derived: sum of 3 quarters · filed 2026-08-04 | $17.84M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $5.79M 10-Q · filed 2026-05-06 | $12.35M derived: sum of 2 quarters · filed 2026-05-06 | $18.04M derived: sum of 3 quarters · filed 2026-05-06 | $24.21M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $12.25M derived: sum of 2 quarters · filed 2026-03-05 | $18.42M derived: sum of 3 quarters · filed 2026-03-05 | $24.78M 10-K · filed 2026-03-05 |
| 2024-09-30 | $5.69M 10-Q · filed 2025-11-07 | $11.86M derived: sum of 2 quarters · filed 2025-11-07 | $18.22M 10-Q · filed 2025-11-07 | $27.07M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $6.17M 10-Q · filed 2025-08-08 | $12.53M 10-Q · filed 2025-08-08 | $21.39M derived: sum of 3 quarters · filed 2026-03-05 | $29.26M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $6.36M 10-Q · filed 2025-05-09 | $15.21M derived: sum of 2 quarters · filed 2026-03-05 | $23.09M derived: sum of 3 quarters · filed 2026-03-05 | $30.36M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $8.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $16.73M derived: sum of 2 quarters · filed 2026-03-05 | $24.00M derived: sum of 3 quarters · filed 2026-03-05 | $30.96M 10-K · filed 2026-03-05 |
| 2023-09-30 | $7.87M 10-Q · filed 2024-11-08 | $15.14M derived: sum of 2 quarters · filed 2024-11-08 | $22.11M 10-Q · filed 2024-11-08 | $28.74M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $7.27M 10-Q · filed 2024-08-08 | $14.23M 10-Q · filed 2024-08-08 | $20.87M derived: sum of 3 quarters · filed 2025-03-17 | $29.16M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $6.96M 10-Q · filed 2024-05-09 | $13.60M derived: sum of 2 quarters · filed 2025-03-17 | $21.89M derived: sum of 3 quarters · filed 2025-03-17 | $30.21M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $6.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $14.93M derived: sum of 2 quarters · filed 2025-03-17 | $23.25M derived: sum of 3 quarters · filed 2025-03-17 | $31.78M 10-K · filed 2025-03-17 |
| 2022-09-30 | $8.29M 10-Q · filed 2023-11-09 | $16.61M derived: sum of 2 quarters · filed 2023-11-09 | $25.15M 10-Q · filed 2023-11-09 | $34.77M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $8.32M 10-Q · filed 2023-08-04 | $16.85M 10-Q · filed 2023-08-04 | $26.48M derived: sum of 3 quarters · filed 2024-02-27 | $36.13M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $8.53M 10-Q · filed 2023-05-05 | $18.16M derived: sum of 2 quarters · filed 2024-02-27 | $27.82M derived: sum of 3 quarters · filed 2024-02-27 | $36.75M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $19.28M derived: sum of 2 quarters · filed 2024-02-27 | $28.22M derived: sum of 3 quarters · filed 2024-02-27 | $37.45M 10-K · filed 2024-02-27 |
| 2021-09-30 | $9.65M 10-Q · filed 2022-11-04 | $18.59M derived: sum of 2 quarters · filed 2022-11-04 | $27.82M 10-Q · filed 2022-11-04 | $36.03M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $8.94M 10-Q · filed 2022-08-05 | $18.17M 10-Q · filed 2022-08-05 | $26.38M derived: sum of 3 quarters · filed 2023-03-03 | $35.94M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $9.23M 10-Q · filed 2022-05-06 | $17.44M derived: sum of 2 quarters · filed 2023-03-03 | $27.00M derived: sum of 3 quarters · filed 2023-03-03 | $34.70M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $17.77M derived: sum of 2 quarters · filed 2023-03-03 | $25.47M derived: sum of 3 quarters · filed 2023-03-03 | $37.20M 10-K · filed 2023-03-03 |
| 2020-09-30 | $9.56M 10-Q · filed 2021-11-05 | $17.26M derived: sum of 2 quarters · filed 2021-11-05 | $28.99M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $7.70M 10-Q · filed 2021-08-06 | $19.43M 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $11.73M 10-Q · filed 2021-05-07 | |||
| 2019-09-30 | $8.09M 10-Q · filed 2020-11-06 | $15.46M derived: sum of 2 quarters · filed 2020-11-06 | $23.63M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $7.37M 10-Q · filed 2020-08-07 | $15.54M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $8.17M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |